Joint Effect Of Peroxisome Proliferator-Activated Receptor Gamma Genetic Polymorphisms And Estrogen-Related Risk Factors On Breast Cancer Risk: Results From A Case-Control Study In Taiwan

Peroxisome proliferator-activated receptor gamma (PPAR gamma) has been linked with possible antineoplastic effects in colorectal carcinogenesis. However, data for the possible link between PPAR gamma and breast cancer risk are sparse. We assessed the association of three polymorphisms in PPAR gamma (rs10865710 [C-681T], rs1805192 [Pro12Ala], and rs3856806 [C1431T]) with the risk of breast cancer in an ethnic Chinese female population in Taiwan. In addition, interactions with estrogen exposures were also explored. Genotypes for the PPAR gamma polymorphisms were determined on 291 incident breast cancer cases and 589 matched controls by fluorogenic 5'-nuclease assay. The at-risk haplotypes were defined according to the three polymorphisms in the following order: C-681T, Pro12Ala, and C1431T, which include CCT, GGT, and GGC. In addition, a critical period of estrogen exposure was estimated by the interval between age at menarche and age at first full-term pregnancy. Overall, there was no evidence of a significant impact of individual polymorphisms of PPAR gamma on breast cancer risk. However, the haplotype analysis revealed that women harboring at-risk haplotypes showed a significant 67% increase in breast cancer risk [adjusted odds ratio (OR) 1.67; 95% confidence interval (CI) 1.11-2.52]. Furthermore, there was a significant joint effect of estrogen exposure-related factors and at-risk haplotypes of PPAR gamma on breast cancer risk (adjusted OR 4.04; 95% CI 1.89-8.65), particularly in premenopausal women. The present study implicates a role for PPAR gamma in breast cancer risk. Mechanistic studies to fully elucidate the mechanisms underlying PPAR gamma's effects should be pursued in future investigations.